Methylene blue for management of ifosfamide-induced encephalopathy

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 299-303

  Patel, Priti N ^a,b  

^a Department of Clinical Pharmacy Practice ^*  (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

Encephalopathy; Ifosfamide; Methylene blue; Neurotoxicity

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GLUCOSE; HALOPERIDOL; IFOSFAMIDE; LORAZEPAM; MESNA; METHYLENE BLUE; THIAMINE; TOPOTECAN;

AGITATION; BRAIN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG MECHANISM; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; EWING SARCOMA; HUMAN; IFOSFAMIDE INDUCED ENCEPHALOPATHY; METASTASIS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SECONDARY PREVENTION; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

HUMANS; IFOSFAMIDE; MEDLINE; METHYLENE BLUE; NEUROTOXICITY SYNDROMES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33144486282     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G114     Document Type: Review

References (28)

1. Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988;80:556-66.
2. Furlanut M, Franceschi L. Pharmacology of ifosfamide. Oncology 2003;65(suppl 2):2-6.
3. Turner AR, Duong CD, Good DJ. Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol 2003;15:435-9.
4. Anderson NR, Tandon DS. Ifosfamide extrapyramidal neurotoxicity. Cancer 1991;68:72-5.
5. Gonzales-Angulo AM, Orzano JA, Davila E. Ifosfamide-induced encephalopathy. South Med J 2002;95:1215-7.
6. DiMaggio JR, Brown R, Baue WF, Schapira D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994;73:1509-14.
7. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy (letter). N Engl J Med 1995;332:1239-40.
8. Raj AB, Bertolone SJ, Jaffe N. Methylene blue reversal of ifosfamide-related encephalopathy (letter). J Pediatr Hematol Oncol 2004;26:116.
9. McVay JI, Wood AM. Suspected ifosfamide-induced neurotoxicity. Pharmacotherapy 1999;19:1450-5.
10. Klastersky J. Side effects of ifosfamide. Oncology 2003;65(suppl 2):7-10.
11. Reiger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004;15:347-50.
12. Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology 2003;65(suppl 2):11-6.
13. Simonian NA, Gilliam FG, Chiappa KH. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology 1993;43:2700-2.
14. Buesa JM, Garcia-Teijido P, Losa R, Fra J. Treatment of ifosfamide encephalopathy with intravenous thiamin (letter). Clin Cancer Res 2003;9:4636-7.
15. Peter C, Hongwan D, Kupfer A. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000;56:247-50.
16. Donegan S. Novel treatment for the management of ifosfamide neurotoxicity: rationale for the use of methylene blue. J Oncol Pharm Practice 2001;6:153-65.
17. Kasper B, Harter C, Meissner J, et al. Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? Support Care Cancer 2004;12:205-7.
18. Meanwell CA, Blake AE, Latief TN, et al. Encephalopathy associated with ifosphamide/mesna therapy (letter). Lancet 1985;1:406-7.
19. Kerbusch T, de Kraker J, Keizer J, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001;40:41-62.
20. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989;49:753-7.
21. Cerny T, Castiglione M, Brunner K, Kupfer A, Martinelli G, Lind M. Ifosfamide by continuous infusion to prevent encephalopathy (letter). Lancet 1990;335:175.
22. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986;22:815-9.
23. Burlet RA, Conner CS. Methylene blue. In: Klasco RK, ed. DRUGDEX System (electronic version). Greenwood Village, CO: Thomson Micromedex. www.thomsonhc.com (accessed 2005 Jan 15).
24. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996;50:249-52.
25. Alonso JL, Nieto Y, Lopez JA, Martin M, Diaz-Rubio E. Ifosfamide encephalopathy and methylene blue: a case report (letter). Ann Oncol 1996;7:643-5.
26. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000;82:291-4.
27. Common terminology criteria for adverse events v3.0. Bethesda, MD: National Cancer Institute, 2003.
28. Kupfer A, Aeschlimann C. Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 1994;343:763-4.